ישראל - עברית - Ministry of Health

eli lilly israel ltd, israel - teriparatide - תמיסה להזרקה - teriparatide 250 mcg/ml - teriparatide - teriparatide - treatment of postmenopausal women with osteoporosis at high risk for fracture:forteo is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. in postmenopausal women with osteoporosis, forteo increases bmd reduces the risk of vertebral and nonvertebral fractures . increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture :forteo is indicated to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy . treatment of men and women with glucocorticoid-induced osteoporosis at high risk for fracture:forteo is indicated for the treatment of men and women with osteopo

ישראל - עברית - Ministry of Health

dexcel ltd, israel - teriparatide - תמיסה להזרקה - teriparatide 250 mcg/ml - teriparatide

ישראל - עברית - Ministry of Health

abic marketing ltd, israel - teriparatide as acetate - תמיסה להזרקה - teriparatide as acetate 250 mcg/ml - teriparatide

ישראל - עברית - Ministry of Health

kamada ltd, israel - teriparatide - תמיסה להזרקה - teriparatide 0.250 mg / 1 ml - teriparatide

ישראל - עברית - Ministry of Health

amgen europe b.v. - romosozumab - תמיסה להזרקה - romosozumab 90 mg / 1 ml - romosozumab

ישראל - עברית - Ministry of Health

csl behring ltd., israel - coagulation factor ii (human); coagulation factor ix (human- rfixfc); coagulation factor vii (human); coagulation factor x (human); protein c; protein s antigen - אבקה וממס להכנת תמיסה להזרקה - coagulation factor ii (human) 200 - 480 iu; coagulation factor vii (human) 100 - 250 iu; coagulation factor ix (human- rfixfc) 200 - 310 iu; coagulation factor x (human) 220 - 600 iu; protein c 150 - 450 iu; protein s antigen 120 - 380 iu - coagulation factor ix, ii, vii and x in combination - coagulation factor ix, ii, vii and x in combination - -treatment and perioperative prophylaxis of bleedings in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin k antagonists, or in case of overdose of vitamin k antagonists, when rapid correction of the deficiency is required.

ישראל - עברית - Ministry of Health

teva medical marketing ltd. - coagulation factor viii recombinant 250 iu/vial - powder for solution for injection - coagulation factor viii - the use of recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).recombinate is also indicated in the perioperative management of patients with haemophilia a. recombinate is appropriate for use in children of all ages including the newborn. (safety and efficacy studies have been performed in both previously treated and previously untreated children). the product in not suitable for the treatment of von willebrand's disease.

ישראל - עברית - Ministry of Health

teva medical marketing ltd. - coagulation factor viii recombinant 1000 iu/vial - powder for solution for injection - coagulation factor viii - the use of recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). recombinate is also indicated in the perioperative management of patients with haemophilia a. recombinate is appropriate for use in children of all ages including the newborn. (safety and efficacy studies have been performed in both previously treated and previously untreated children). the product in not suitable for the treatment of von willebrand's disease.

ישראל - עברית - Ministry of Health

teva medical marketing ltd. - coagulation factor viii recombinant 500 iu/vial - powder for solution for injection - coagulation factor vii - the use of recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). recombinate is also indicated in the perioperative management of patients with haemophilia a. recombinate is appropriate for use in children of all ages including the newborn. (safety and efficacy studies have been performed in both previously treated and previously untreated children). the product in not suitable for the treatment of von willebrand's disease.

ישראל - עברית - Ministry of Health

pharmalogic ltd - ceftriaxone as sodium - אבקה להמסה להזרקה\אינפוזיה - ceftriaxone as sodium 1 g/vial - ceftriaxone - ceftriaxone - treatment of infections caused by pathogens sensitive to ceftriaxone, e.g.: sepsis, meningitis, abdominal infections (peritonitis, infection of the biliary and gastrointestinal tract), infections of the bones, loints, soft tissue, skin and of wounds, infections in patients with impaired defense mechanisms, renal and urinary tract infections, respiratory tract infections, particularly pneumonia, and ear, nose and throat infections, genital infections including gonorrhea. perioperative prophylaxis of infections.